JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines

Experimental Hematology & Oncology

Zhizhuang Joe Zhao²  Xueqi Fu²  Wanting Tina Ho¹  Yanhong Du¹  Wanke Zhao¹ 

[1] Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA;Edmond H. Fischer Signal Transduction Laboratory, College of Life Sciences, Jilin University, Changchun, China

关键词: Transformation;    Mutations;    Leukemia;    TP53;    JAK2;   

Others  :  814787
DOI  :  10.1186/2162-3619-1-15

 received in 2012-05-18, accepted in 2012-06-21,  发布年份 2012

【 摘 要 】

Background

JAK2V617F, a gain-of-function mutant form of tyrosine kinase JAK2, is found in the majority of patients with Ph- myeloproliferative neoplasms (MPNs), a group of chronic hematological diseases that often lead to acute leukemia. The current study is intended to find other gene mutations that collaborate with JAK2V617F to cause leukemic transformation.

Methods

Total RNA and genomic DNA were isolated from two JAK2V617F-positive cell lines, namely, erythroleukemic HEL and megakaryoblastic leukemic SET-2 cells. Candidate genes were amplified by PCR and further sequenced.

Results

Homozygous mutations of the TP53 gene which encodes tumor suppressor p53 were found in HEL and SET-2 cells. While HEL cells, which have homozygous JAK2V617F, contain a rare M133K p53 mutation, SET-2 cells, which have a heterozygous JAK2V617F mutation, contain a common R248W p53 alteration. Western blot analyses revealed high levels of p53 expression in both cells. M133K and R248W are located in the DNA binding domain of p53. Structural analyses revealed that they potentially disrupt the interaction of p53 with DNA, thereby causing loss of p53 function.

Conclusions

JAK2V617F and p53 mutations coexist in leukemia cells. We believe that JAK2V617F is able to drive leukemic transformation when the function of tumor suppressor p53 is lost. The interplay of JAK2V617F with p53 may affect the progression of MPNs.

【 授权许可】

   
2012 Zhao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Levine RL, Pardanani A, Tefferi A, Gilliland DG: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7:673-683.
• [2]Zhao W, Gao R, Lee J, Xing S, Ho WT, Fu X, Li S, Zhao ZJ: Relevance of JAK2V617F positivity to hematological diseases–survey of samples from a clinical genetics laboratory. J Hematol Oncol 2011, 4:4. BioMed Central Full Text
• [3]Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ: Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280:22788-22792.
• [4]Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X, Li Q, Fu X, Xu M, Zhao ZJ: Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008, 111:5109-5117.
• [5]Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG: Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, 115:3589-3597.
• [6]Ferbeyre G, Lowe SW: The price of tumour suppression? Nature 2002, 415:26-27.
• [7]Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28:622-629.
• [8]Donehower LA, Lozano G: 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 2009, 9:831-841.
• [9]Liu Y, Elf SE, Asai T, Miyata Y, Liu Y, Sashida G, Huang G, Di Giandomenico S, Koff A, Nimer SD: The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle 2009, 8:3120-3124.
• [10]Quentmeier H, MacLeod RA, Zaborski M, Drexler HG: JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006, 20:471-476.
• [11]Martin P, Papayannopoulou T: HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 1982, 216:1233-1235.
• [12]Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S, Matsumura I, Hanada S, Arima T: Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia 2000, 14:142-152.
• [13]Zhao AH, Gao R, Zhao ZJ: Development of a highly sensitive method for detection of JAK2V617F. J Hematol Oncol 2011, 4:40. BioMed Central Full Text
• [14]Sutton BC, Allen RA, Zhao ZJ, Dunn ST: Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark 2007, 3:315-324.
• [15]Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265:346-355.
• [16]Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T: Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008, 22:1539-1541.
• [17]Gaidano G, Pastore C, Santini V, Nomdedeu J, Gamberi B, Capello D, Vischia F, Resegotti L, Mazza U, Ferrini PR, Lo Coco F, Saglio G: Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. Genes Chromosomes Cancer 1997, 19:250-255.
• [18]Tsurumi S, Nakamura Y, Maki K, Omine M, Fujita K, Okamura T, Niho Y, Hashimoto S, Kanno K, Suzuki K, Hangaishi A, Ogawa S, Hirai H, Mitani K: N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol 2002, 71:131-133.
• [19]Donehower LA: p53: guardian AND suppressor of longevity? Exp Gerontol 2005, 40:7-9.
• [20]Serrano M, Blasco MA: Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol 2007, 8:715-722.
• [21]Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, Flores JM, Vina J, Blasco MA, Serrano M: Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007, 448:375-379.
• [22]Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E, Vainchenker W, Plo I: JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2012, 31:1323-1333.
• [23]Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ: Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007, 282:3428-3432.